Retrogenix's cell microarray technology is the leading solution for discovering the human primary receptors and off-targets for antibodies, proteins, small molecules, viruses and other complex ligands such as CAR T cells. We discover high quality, exploitable drug targets and mechanisms of action for our global pharmaceutical clients as well as screening their potential therapeutics for specificity in order to inform lead selection and assist with safety assessment. Specific receptor interactions are identified by screening against the most comprehensive set of human plasma membrane proteins available in the context of the human cell. Now covering more than 6,200 proteins, this represents the majority of known cell surface proteins and contributes to the unrivalled success rates of the technology. Retrogenix works with small biotechs and leading academic groups through to major pharmaceutical companies, currently helping all of the world’s top twenty drug developers to bring new therapeutics to market faster. Retrogenix was acquired by Charles River in March 2021.